• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

    11/14/24 9:30:22 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYMR alert in real time by email
    SC 13G/A 1 p24-3101sc13ga.htm KYMERA THERAPEUTICS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    Kymera Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    501575104

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    þ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 50157510413G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Avoro Capital Advisors LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) þ

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    7,750,000 (including 3,250,000 shares of Common Stock issuable upon exercise of Warrants) (see Item 4)*

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    7,750,000 (including 3,250,000 shares of Common Stock issuable upon exercise of Warrants) (see Item 4)*

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,750,000 (including 3,250,000 shares of Common Stock issuable upon exercise of Warrants) (see Item 4)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%

    12

    TYPE OF REPORTING PERSON

    OO, IA

             

     

    * As more fully described in Item 4, the Warrants (as defined below) are subject to the 9.99% Blocker (as defined below) and the percentage set forth in row (11) gives effect to such blocker. However, rows (5), (7) and (9) show the number of shares of Common Stock that would be issuable upon the exercise in full of the Warrants and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (5), (7) and (9).

     

     

    CUSIP No. 50157510413G/APage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Behzad Aghazadeh

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) þ

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    7,750,000 (including 3,250,000 shares of Common Stock issuable upon exercise of Warrants) (see Item 4)*

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    7,750,000 (including 3,250,000 shares of Common Stock issuable upon exercise of Warrants) (see Item 4)*

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,750,000 (including 3,250,000 shares of Common Stock issuable upon exercise of Warrants) (see Item 4)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    * As more fully described in Item 4, the Warrants (as defined below) are subject to the 9.99% Blocker (as defined below) and the percentage set forth in row (11) gives effect to such blocker. However, rows (5), (7) and (9) show the number of shares of Common Stock that would be issuable upon the exercise in full of the Warrants and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (5), (7) and (9).

     

     

    CUSIP No. 50157510413G/APage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER
       
      Kymera Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
       
      500 North Beacon Street, 4th Floor, Watertown, MA 02472

     

    Item 2(a). NAME OF PERSON FILING
       
      This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company (“Avoro”), which provides investment advisory and management services and has acquired the securities of the Issuer solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh (“Dr. Aghazadeh,” and together with Avoro, the “Reporting Persons”), who serves as the portfolio manager and controlling person of Avoro.
       
      The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012.

     

    Item 2(c). CITIZENSHIP
       
      Avoro is a Delaware limited liability company.  Dr. Aghazadeh is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e). CUSIP NUMBER
       
      501575104

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;

     

    CUSIP No. 50157510413G/APage 5 of 7 Pages

     

      (e) þ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) þ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:  

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference.
       
      The percentage set forth in Row 11 of this Schedule 13G is calculated based upon 64,583,776 shares of Common Stock outstanding, which is the sum of 61,753,243 shares of Common Stock outstanding as of August 2, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission on August 7, 2024 and a total of 2,830,533 shares of Common Stock issued in the Issuer’s underwritten offering (including the exercise in full of the underwriter’s overallotment option), as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 20, 2024, and assumes the exercise of certain pre-funded warrants (the “Warrants”) to purchase Common Stock of the Company held by Avoro Life Sciences Fund LLC up to the 9.99% Blocker (as defined below).
       
      Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding shares of Common Stock (the “9.99% Blocker”) and the percentage set forth in Row (11) of the cover page for each Reporting Person gives effect to the 9.99% Blocker.  Consequently, at this time, the Reporting Persons are not able to exercise all of such Warrants due to the 9.99% Blocker.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
       
      Not applicable.

     

    CUSIP No. 50157510413G/APage 6 of 7 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      See Item 2.  Avoro Life Sciences Fund LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      Not applicable.

     

    Item 10. CERTIFICATION
       
      Each Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 50157510413G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 14, 2024

     

    AVORO CAPITAL ADVISORS LLC  
       
       
    /s/ Scott Epstein  
    Name: Scott Epstein  
    Title:

    Chief Financial Officer

    & Chief Compliance Officer

     
       
       
    /s/ Behzad Aghazadeh  
    BEHZAD AGHAZADEH  

     

     

     

     

    Get the next $KYMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KYMR

    DatePrice TargetRatingAnalyst
    3/13/2025$52.00Buy
    Citigroup
    12/10/2024$60.00Buy
    BTIG Research
    12/6/2024$55.00Market Perform
    BMO Capital Markets
    12/2/2024$57.00Equal Weight → Overweight
    Wells Fargo
    11/18/2024$65.00Overweight
    Stephens
    9/9/2024$60.00Outperform
    Leerink Partners
    8/26/2024$65.00Peer Perform → Outperform
    Wolfe Research
    4/22/2024$53.00Outperform
    Oppenheimer
    More analyst ratings

    $KYMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

      SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      11/14/24 4:31:20 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

      SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      11/14/24 1:22:39 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

      SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      11/14/24 9:30:22 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Kymera Therapeutics with a new price target

      Citigroup initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $52.00

      3/13/25 8:12:58 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on Kymera Therapeutics with a new price target

      BTIG Research initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $60.00

      12/10/24 8:28:42 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Kymera Therapeutics with a new price target

      BMO Capital Markets initiated coverage of Kymera Therapeutics with a rating of Market Perform and set a new price target of $55.00

      12/6/24 7:53:24 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

      IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA IND-enabling studies are ongoing with Phase 1 testing expected to

      5/9/25 7:01:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

      Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it will host a video webcast from 10:00 a.m. to 11:30 a.m. ET on Friday, May 9, 2025. The company will report first quarter 2025 financial results and also disclose its new oral development candidate targeting a high value undrugged target for multiple autoimmune and rheumatic diseases. Additionally, the Company will review highlights and upcoming milestones across its industry-leading immunology pipeline. To join the video call or view the li

      4/24/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

      WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of diverse experience in the life sciences industry to Kymera and will lead business development strategy and activities for the company. "We continue to stay focused on our mission of building a fully integrated biopharmaceutical company focused on discovering and developing oral drugs with biologics-like activity," said Nello Mainolfi, Ph.D., Founder,

      4/9/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Goodman Noah was granted 50,000 shares, increasing direct ownership by 61,396% to 50,081 units (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      4/9/25 8:05:05 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Goodman Noah claimed ownership of 81 shares (SEC Form 3)

      3 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      4/9/25 8:00:05 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Jacobs Bruce N. exercised 25,000 shares at a strike of $2.08, increasing direct ownership by 12% to 226,886 units (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      4/1/25 8:00:03 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

      IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA IND-enabling studies are ongoing with Phase 1 testing expected to

      5/9/25 7:01:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

      Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not to advance KT-295 (TYK2) into further clini

      5/9/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

      WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV on May 14, 2025, at 3:40 p.m. PT. A live webcast of the presentation will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.  About Kymera TherapeuticsKymera is a clinical-stage biotechnology company

      5/7/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $46 worth of shares (1 units at $46.41) (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      8/22/24 4:03:26 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bvf Partners L P/Il bought $5,301,325 worth of shares (414,105 units at $12.80) (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      11/6/23 6:07:28 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Financials

    Live finance-specific insights

    See more
    • Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

      Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not to advance KT-295 (TYK2) into further clini

      5/9/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected to initiate in 2Q25 with data in 4Q25, followed by two parallel Phase 2b trials in AD and asthma starting in 4Q25 and 1Q26, respectively KT-295 (TYK2) Phase 1 trial is expected to start in 2Q25, with data expected in 4Q25 KT-474/SAR444656 (IRAK4) Phase 2b trials in hidradenitis suppurativa (HS) and AD ongoing, led by partner Sanofi, with primary completion of both trials expected by mid-2026 New oral degrader program against a high-value immunology target to be announced in early May 2025 in a company webcast Well-capitali

      2/27/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

      WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, will report fourth quarter and full year 2024 financial results on February 27, 2025. The Company will host a new video conference call format at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Ky

      2/20/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Kymera Therapeutics Inc.

      10-Q - Kymera Therapeutics, Inc. (0001815442) (Filer)

      5/9/25 7:15:41 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)

      5/9/25 7:05:06 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.

      SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      4/30/25 11:12:25 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care